Understanding What Matters Most to Patients: Establishing the Validity of a Best-Worst Scaling Survey

UNC Lineberger Comprehensive Cancer Center

Status: Completed

Conditions: Hematologic Neoplasms

Treatments: Other: Qualitative Interviews; Other: Assessment Surveys

Study type: Observational

Funder types: Other; NIH

Identifiers

NCT05061095

U2CNR014637 (U.S. NIH Grant/Contract)

LCCC 2136

Details and patient eligibility

About

This study will evaluate the validity of using a survey to quantify patient preferences at the point-of-care and the potential effectiveness of the survey to improve goal-concordant care. The primary hypothesis is that by identifying the strength of patient preferences for outcomes with this survey clinicians will be able to improve goal-concordant care by aligning clinical recommendations with patients' preferences. This study will have 50 patients with newly diagnosed hematologic malignancy complete the survey throughout their disease course (up to 2 years) and conduct qualitative interviews with a subset (n = 20) of participants. The information obtained from these participants will be used to refine the survey. Interviews with oncologists and palliative care specialists (up to 10) will inform implementation.

Enrollment: 51 patients

Sex: All

Ages: 60+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Confirmed new diagnosis of one of the following hematologic malignancies: aggressive lymphoma, multiple myeloma, CLL, CML, AML, ALL, MDS EB1 or EB2
• Age≥60
• Ability to read, understand, and communicate fluently in English
• Ability to understand and comply with study procedures
• Willingness and ability to provide written informed consent

Exclusion criteria

• Dementia, altered mental status, or psychiatric condition that would prohibit the understanding or rendering of informed consent or participation in the discrete choice experiment.
• Significant medical conditions, as assessed by the investigators, that would substantially increase the burden on the patient to complete study assessments (such as multiorgan failure, respiratory failure, or other critical illness).

Trial design